About Us
Founded in Basel, Switzerland, in 20215 Accelero empowers healthcare early-stage and growth-stage companies to raise and manage capital with confidence. From planning capital raising, strategy development, to securing investor commitments, we provide end-to-end support tailored to your stage, model, and vision.
We craft compelling pitch materials, develop robust financial models that validate your raise and serve as operational roadmaps. We also guide you through investor targeting, outreach, and deal structuring. Leveraging our extensive network, we connect you with the right investors. Always aligned with your sector, stage, and goals.
Beyond fundraising, we help you scale with discipline. By setting clear KPIs, aligning resources, and adapting financial models, we ensure capital fuels measurable progress and sustainable growth.
Our mission is simple: raise smart, grow efficiently, and scale with confidence.
Our Services
From early strategy to commercialization, we ensure your growth stays on track.
Discovery &
Insight
We turn deep analysis of your science, market, and strategy into clear pathways for funding, partnerships, and market success.
Capital &
Partner Access
Our global network helps you secure investment, forge pharma partnerships, and gain expert guidance to accelerate your biotech’s growth.
Strategy &
Design
We partner with you to design strategies that attract capital, forge licensing deals, and maximize long-term market value.
Execution & Transformation
By standing with you through execution, governance, and change, we ensure your biotech strategy delivers market traction, investor confidence, and lasting value.
Accelero Insights
10
Years of Excellence
>500m
In transactions advised
25+
Partnering Transactions
15+
Transformation guided
Meet the Team
Meet Our Team
Detlef Krawinkel
As CEO and Founder Detlef brings over a decade of experience guiding biotech and medtech leaders through critical growth phases. He specializes in strategy, capital access, and board-level advisory.
Dr. Barbara Troup
Barbara is an expert on organizational change and leadership communication. She supports life science companies in navigating transformation with clarity and impact.
Dr. Peter Stagier
Peter combines financial acumen with deep capital raising expertise and forecasting. He advises on cost-effective scale-up and investment planning for life science companies.
Edward Gudaitis
Edward is a seasoned commercial strategist with a track record in biotech and pharma. He guides clients in building competitive go-to-market strategies and securing licensing deals.
Bertrond Bonnot
Bertrand has extensive experience in market entry and international business development. He helps innovators unlock new geographies and build sustainable partnerships.
Ruben Giorgino
Ruben brings extensive experience in pre-clinical clinical development across pharma and rare diseases. He supports companies in advancing therapies from research through clinical trials, ensuring scientific rigor and regulatory alignment.
Dr. Peter Schiemann
Peter brings decades of experience in product manufacturing and global labeling compliance. He supports companies in delivering reliable, regulatory-compliant products worldwide.
Beat
Widler
Beat is a recognized specialist in regulatory affairs, quality management, and pharmacovigilance. He ensures clients meet compliance standards while accelerating approvals.
Our Edge
1
Track Record
Proven in delivering funding, partnerships, and strategies for growth.
2
Global Network
Access to top-tier investors and partners.
3
Boutique Focus
Personalised, senior-level attention on every engagement.
4
Embedded Support
Globally connected, we act as an extension of your leadership team.
Client Stories
A European biotech lacked clarity on strategy, clinical and fundraising priorities. Accelero aligned leadership with a 24-month roadmap, connected with its investor network, enabling a €20M capital raise and a strategic US pharma co-development deal.
CEO Rare Disease Company
A European company struggled to secure investors or partners. Accelero reframed its strategy, refined the value proposition and outreached into the market while activating its global networks, leading to a $15M Series A Capital Raise.
CEO Cellular Medicine
A European biotech was seeking the right partner to advance its breakthrough therapy. Accelero reshaped the partnering strategy, and leveraged its global network, leading to a licensing agreement with a leading pharma company. The deal secured a double-digit million first milestone alongside highly attractive royalty payments.
CEO Longevity Company
Partnerships
Book your free 30-minute consultation and take the first step toward unlocking your growth potential.